A Novel Strategy for Inhibiting Growth of Human Pancreatic Cancer Cells by Blocking Cyclin-Dependent Kinase Activity

被引：18

作者：

Iseki H. ^{[1
]}

Ko T.C. ^{[1
,2
]}

Xue X.Y. ^{[1
]}

Seapan A. ^{[1
]}

Townsend Jr. C.M. ^{[1
]}

机构：

[1] Department of Surgery, University of Texas Medical Branch, Galveston, TX

[2] Department of Surgery, University of Texas Medical Branch, Galveston, TX 77555-0542

来源：

Journal of Gastrointestinal Surgery | 1998年 / 2卷 / 1期

基金：

美国国家卫生研究院;

关键词：

Pancreatic Cancer; Pancreatic Cancer Cell; Pancreatic Cancer Cell Line; Human Pancreatic Cancer Cell; Cdk2 Activity;

D O I：

10.1016/S1091-255X(98)80101-7

中图分类号：

学科分类号：

摘要：

Pancreatic cancers frequently carry mutations in the K-ras, p53, and p16 genes, which regulate cell proliferation. Transition from G1 to S phase of the cell cycle requires activation of cyclin-dependent kinase 2 (Cdk2), which is inhibited by olomoucine and roscovitine. The purpose of this study was to determine whether olomoucine and roscovitine can block Cdk2 kinase activity and inhibit proliferation of four human pancreatic cancer cell lines with various genetic alterations. Human pancreatic carcinoma cell lines BxPC-3, PANC-1, Capan-2, and CAV were treated with olomoucine or roscovitine. Cdk2 kinase activity was determined using histone H1 as the substrate. Cell cycle distribution was analyzed by DNA flow cytometry. Cell numbers were quantitated by Coulter counter. Olomoucine and roscovitine blocked Cdk2 activity in all four pancreatic cancer cell lines. Both compounds also inhibited cell proliferation in a dose-dependent fashion. Roscovitine was at least threefold more potent than olomoucine for both Cdk2 activity and cell proliferation. We have shown that Cdk inhibitors, olomoucine and roscovitine, block proliferation of human pancreatic cancer cells regardless of their mutations in K-ras, p53, or p16 genes. These compounds represent a novel therapeutic strategy with potential therapeutic benefits for pancreatic cancers.

引用

页码：36 / 43

页数：7

共 36 条

[1]

Parker S.L., Tong T., Bolden S., Wingo P.A., Cancer Statistics, 1997, CA Cancer J Clin, 47, pp. 5-27, (1997)

[2]

Reber H.A., Ashley S.W., McFadden D., Curative treatment for pancreatic neoplasms. Radical resection, Surg Clin North Am, 75, pp. 905-912, (1995)

[3]

Abrams R.A., Grochow L.B., Adjuvant therapy with chemotherapy and radiation therapy in the management of carcinoma of the pancreatic head, Surg Clin North Am, 75, pp. 925-938, (1995)

[4]

Martin J., Arnheim N., Perucho M., Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes, Cell, 53, pp. 549-554, (1988)

[5]

Kalthoff H., Schmiegel W., Roeder C., Kasche D., Schmidt A., Lauer G., Thiele H.G., Honold G., Pantel K., Riethmuller G., Scherer E., Maurer J., Maacke H., Deppert W., p53 and K-ras alterations in pancreatic epithelial cell lesions, Oncogene, 8, pp. 289-298, (1993)

[6]

Pellegata N.S., Sessa F., Renault B., Bonato M., Leone B.E., Solcia E., Ranzani G.N., K-ras and p53 gene mutations in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions, Cancer Res, 54, pp. 1556-1560, (1994)

[7]

Redson M.S., Caldas C., Seymour A.B., Hruban R.H., Da Costa L., Yeo C.J., Kern S.E., p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions, Cancer Res, 54, pp. 3025-3033, (1994)

[8]

Caldas C., Hahn S.A., Da Costa L.T., Redston M.S., Schutte M., Seymour A.B., Weinstein C.L., Hruban R.H., Yeo C.J., Kern S.E., Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma, Nature Genet, 8, pp. 27-32, (1994)

[9]

Van Den Heuvel S., Harlow E., Distinct roles for cyclin-dependent kinases in cell cycle control, Science, 262, pp. 2050-2054, (1993)

[10]

Nigg E.A., Cyclin-dependent protein kinases: Key regulators of the eukaryotic cell cycle, Bioessays, 17, pp. 471-480, (1995)

← 1 2 3 4 →